Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amarin Corporation PLC (NASDAQ:AMRN)

3.19
Delayed Data
As of Sep 30
 +0.06 / +1.92%
Today’s Change
1.24
Today|||52-Week Range
3.46
+68.78%
Year-to-Date
Will Amarin (AMRN) Continue to Surge Higher?
Sep 29 / Zacks.com - Paid Partner Content
Biotech Stocks Under $5: 2 to Buy, 1 to Avoid
Sep 24 / MotleyFool.com - Paid Partner Content
Amarin Corporation (AMRN) Looks Good: Stock Adds 6.1% in Session
Sep 27 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close3.13
Today’s open3.17
Day’s range3.13 - 3.25
Volume2,460,197
Average volume (3 months)3,097,842
Market cap$653.6M
Dividend yield--
Data as of 3:59pm ET, 09/30/2016

Growth & Valuation

Earnings growth (last year)-159.93%
Earnings growth (this year)+17.86%
Earnings growth (next 5 years)+207.00%
Revenue growth (last year)+51.17%
P/E ratioNM
Price/Sales4.18
Price/Book--

Competitors

 Today’s
change
Today’s
% change
AMRIAlbany Molecular Res...+0.23+1.41%
ARWRArrowhead Pharmaceut...+0.05+0.68%
RGNXRegenxbio Inc+0.13+0.94%
BSTCBiospecifics Technol...+0.84+1.87%
Data as of 4:14pm ET, 09/30/2016

Financials

Next reporting dateNovember 3, 2016
EPS forecast (this quarter)-$0.11
Annual revenue (last year)$81.6M
Annual profit (last year)-$148.8M
Net profit margin-182.32%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
John F. Thero
SVP-
Manufacturing Operations
Derek Kalinowski
Corporate headquarters
Dublin, Dublin

Forecasts

Search for Jobs